Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside ...

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.

Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central nervous system (CNS) evaluation and a multidisciplinary approach, with ...

An expert discusses how structuring clear roles, fostering communication, and using technology in the shared-care model between academic and community centers, alongside monitoring blood glucose ...

Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its ...

An expert discusses how effective use of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN) requires proactive monitoring for capillary leak syndrome, liver toxicity, and ...

Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.

An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing disease-specific targeting and patient fitness, with tagraxofusp remaining the ...

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...